Circadian and ultradian variation is a prominent feature of most endogenous biodynamic processes and has been extensively studied in neuroendocrine systems [1 ] . Interleukin-6 (IL-6) is a multifunctional cytokine that plays an important role in many age-related diseases, including postmenopausal osteoporosis [2, 3 ] . Estrogen has been shown to directly inhibit IL-6 production [4, 5 ] . Very little information on the circadian rhythms and no information on ultradian rhythms of IL-6 or other pro-inflammatory cytokines exists. Recent research has demonstrated a strong reciprocal interaction between IL-6 and the hypothalamic-pituitary-adrenal (HPA) axis [6, 7 ] . Specifically, recombinant IL-6 has been shown to stimulate the HPA axis in humans [8 ] . The recent availability of highly sensitive assays for measuring IL-6 provides the opportunity to study the rhythmic pattern of this cytokine. A study in men, in which samples were collected every 3 h by direct venipuncture, showed a large circadian variation in circulating IL-6 with a peak at 0100 and a nadir at 1000 [9 ] . More frequent sampling is required to elucidate ultradian fluctuations, which typically have periods of 60 to 90 min [10 ] .
For practical reasons, indwelling venous catheters rather than direct venipunctures have been used for studying frequently sampled time series. We designed a study, using an indwelling venous catheter for continuous integrated 15-min sample collection, to establish the normal variations of circulating IL-6 over 24 h in healthy postmenopausal women, and to assess the effect of estrogen replacement therapy on these patterns. In studying the first subject, it became apparent that serum IL-6 reached higher values than expected. Here, we demonstrate that an indwelling peripheral venous catheter leads to local tissue production of IL-6. We also demonstrate that this local production of IL-6 does not affect endogenous cortisol concentrations.
The study protocol was approved by the University of Wisconsin Human Subjects Committee, and the subject gave written informed consent. The study was conducted at the General Clinical Research Center at the University of Wisconsin, Madison.
The subject in this study was a healthy 59-year-old woman who was 6 years postmenopause. A thromboresistant blood withdrawal and tubing set (DakMed, Buffalo, NY) was inserted in a peripheral vein at 0800. Integrated blood samples were collected at 15-min intervals over 25 h by continuous withdrawal with a peristaltic pump (DakMed). Clotted blood samples were centrifuged at 1520g for 10 min, then separated and frozen at Ϫ70°C until IL-6 concentrations were measured in duplicate by a highly sensitive ELISA (Quantakine HS; R & D systems, Minneapolis, MN). This assay kit is validated for measuring IL-6 concentrations in the range 0.094 -10 ng/L. In our laboratory the calibration curve loses linearity at 40 ng/L. The intraassay and interassay CVs for this assay are 3.8% and 7.1%, respectively. The study was repeated after 7 weeks of oral estrogen replacement therapy with 0.625 mg of conjugated estrogen (Premarin) daily. Serum cortisol concentrations were measured in duplicate by RIA (Coat-A-Count, Diagnostic Products Corp.) with an intraassay CV of 10.5%. The reported limit of detection of the assay was 2 g/L (5.5 nmol/L).
Inspection of the first 25-h time series (Fig. 1a ) revealed considerable variation in IL-6 concentrations. IL-6 concentrations remained constant at 2.8 -4.7 ng/L for 3 h after catheter insertion, but this was followed by a steep increase to 35 ng/L, almost 10 times the baseline value, after 20 h of sample collection. The IL-6 concentration at 0900 on the second day was much higher than at 0900 on the first day.
In a repeat study, after 7 weeks of estrogen replacement therapy, a sample was drawn from the contralateral arm by direct venipuncture 11 h after the first sample (Fig. 1b) . The IL-6 in this sample measured 2.6 ng/L, while a simultaneously drawn sample from the indwelling catheter measured 24.2 ng/L. After 12 h of sampling, a new venous catheter was placed in contralateral arm. The concentrations of IL-6 from this new site were initially low but again showed an abrupt increase at 3 h. After 22 h, a new catheter was again placed in an arm vein proximal to the site of the first catheter. This time, the IL-6 concentrations remained high (8 -27 ng/L).
The cortisol concentrations measured in the same serum samples as IL-6 demonstrated a normal diurnal variation, with the peak values at 0530 after a nadir at 0200. No increase in cortisol was seen at the time of the rapid increase in IL-6. After 24 h the cortisol concentrations had returned to baseline value (Fig. 1c) .
The use of indwelling venous catheters for studying time series of hormones is the accepted experimental model. In most instances, hormones are secreted from glandular tissue and the measurements represent the concentrations in the systemic circulation. This case study indicates that the onset of increasing IL-6 concentrations 3 h after catheter insertion most probably represents local production of IL-6 and not the circulating concentrations-which indicates that this sampling method may have limitations when time series of immune mediators (e.g., IL-6) are being assessed. The local production of IL-6 is supported by several lines of evidence. First, the values for IL-6 were markedly lower when drawn by direct venipuncture or through a newly placed catheter from the opposite arm. Secondly, the blood concentrations of IL-6 were higher than values reported in other studies of postmenopausal women that used the same assay system [11, 12 ] . Finally, the morning concentrations of IL-6 in Clinical Chemistry 43, No. 11, 1997 samples drawn upon initial catheter insertion were much lower than those at the same time of day but drawn after the catheter had been in the vein for 24 h.
The increased concentrations of IL-6 found when the third catheter was placed in a vein proximal to the previous site of insertion supports the contention that the high IL-6 values derive from local tissue production rather than from the catheter system itself. Importantly, this local tissue production of IL-6 did not appear to increase the systemic concentrations of the cytokine for at least 12 h and did not seem to stimulate the HPA axis, as evidenced by measured cortisol concentrations.
One can speculate that interruption of the vascular endothelial layer by a venipuncture mediates a cytokine cascade sequence that results in increased IL-6 concentrations. Endothelin, which is produced by endothelial cells, has recently been shown to be a potent stimulator of IL-6 production [13 ] . Other cells at the site of injury, such as vascular smooth muscle cells [14 ] , have also been shown to secrete IL-6. One previous study suggested that the increased concentrations of IL-6 in bolus samples collected via indwelling venous catheters every 3 h for 9 h reflect local production of IL-6 rather than circulating concentrations [15 ] . The continuous sampling, more-frequent measurements, and use of a sensitive IL-6 assay in our study confirm this finding and provide a picture of the timing of this local effect, which in this subject occurred at ϳ3 h.
Because of the local tissue production of IL-6, our study did not allow an assessment of the diurnal variation of IL-6. Although there appears to be a faster increase in IL-6 concentrations during estrogen replacement in this one subject, its exact magnitude is likely to vary, both from time to time and from one vein to another. The main reason for this is variation in the rate of blood flow, which ultimately will dilute the locally secreted IL-6 to various extents.
Our results suggest that circulating concentrations of IL-6 may be more reliably assessed by repeated direct venipunctures at a progressively more-distal venous site each time. However, discomfort and inconvenience associated with this method would obviate frequent sampling in human subjects. Researchers and clinicians measuring IL-6 for diagnostic or monitoring purposes should take into account the sample collection method used, particularly if high concentrations are encountered. This local production of IL-6 occurred as early as 3 h after insertion of a catheter at a fresh site and almost immediately from a catheter inserted downstream (proximal) to a previous catheter insertion site. Whether production of other cytokines is similarly triggered after insertion of a catheter is a matter for future investigation. Several previous reports of increased IL-6 in clinical settings may need reevaluation in view of our findings [16, 17 ] . Common methods for the assay of proteins in biological fluids include Lowry [1] , Coomassie Brilliant Blue G-250 protein dye-binding assay (Bradford) [2] , and the 2,2Ј-bicinchoninic acid (BCA) assay [3] . Among them, the Lowry method has been used widely for protein quantification in biological samples. However, many substances commonly used during protein purification interfere with the Lowry assay. To overcome this, the BCA method was developed. This assay is similar to the Lowry method in that both rely on the biuret reaction for generation of a colored complex between peptide bonds and cuprous ions when protein is placed in an alkaline environment containing Cu 2ϩ . Unlike the Lowry method, the BCA method has been found to have exceptional tolerance to nonionic detergents and simple buffer salts. However, sucrose and detergents, biogenic amines, chlorpromazine, penicillins, vitamin C, paracetamol, hydrogen peroxides, or any compound that can reduce Cu 2ϩ to Cu ϩ will produce the characteristic purple color associated with the binding of Cu ϩ with BCA and interfere with this method [4, 5] . It is not surprising that anthracyclines, which are easily oxidized in alkaline media in the presence of metal ions, would produce the necessary reduction of Cu 2ϩ for the formation of a Cu ϩ -BCA complex. In the Bradford method, the Coomassie blue dye binds to primarily basic and aromatic amino acid residues, especially arginine, and forms colored complexes. In this method, interferences may be caused by drug-protein and (or) drug-dye interactions. Because the mechanism of color formation is different in the BCA and the Bradford methods, both methods were considered for interference studies.
The primary objective of this report was to determine whether an anthracycline, e.g., doxorubicin (Dox), may interfere with the measurement of protein concentrations with the BCA and the Bradford assays. We examined the sensitivity and specificity of the BCA and Coomassie Brilliant Blue for Dox in this study. Such findings may have significant implications in the assay of protein when an anthracycline is present.
Dox showed a significant interference in the BCA assay, whether assayed in the presence or absence of a bovine serum albumin (BSA) protein calibrator (Fig. 1) . The interference was found to be linear over the standard protein range, with an immediate appearance of typical assay color without turbidity (even after further dilutions). The reaction of Dox with the BCA reagent at room temperature (RT) for 2 h suggested that a wide range of anthracyclines will react with the BCA reagent to produce the characteristic purple color if the reduction of Cu 2ϩ to Cu ϩ by anthracyclines is dependent on the anthracycline nucleus rather than on the side-chain substitution. The 
